Title
|
|
|
|
Interruption or discontinuation of tyrosine kinase inhibitor treatment in chronic myeloid leukaemia : a retrospective cohort study (SPARKLE) in Belgium
| |
Author
|
|
|
|
| |
Abstract
|
|
|
|
Objectives: To assess interruptions/discontinuations of tyrosine kinase inhibitor (TKI) treatment in Belgian patients with chronic myeloid leukaemia (CML). Methods: This retrospective study included patients with TKI interruptions/discontinuations of >= 4 continuous weeks (no clinical trial context) between May 2013 and May 2016. Data collection took place between October 2016 and February 2017. Results: All 60 participants (69 interruptions/discontinuations) had chronic-phase CML and 75% had at least a major molecular response (>= MMR) at interruption/discontinuation. Most interruptions/discontinuations occurred while on imatinib (36/69; 49%) and dasatinib (20/69; 29%). Most interruptions/discontinuations occurred due to side effects/intolerance (46/69; 67%); other reasons included a wish to conceive (6/69; 9%) and attempts to achieve treatment-free remission (TFR) (6/69; 9%). Interruptions due to side effects occurred later for imatinib- or dasatinib-treated patients than for those on nilotinib or ponatinib. Treatment was re-initiated in 62% (43/69) of cases. Most interruptions caused by side effects/intolerance were followed by treatment changes. All 4 patients with >= MR 4.5 at interruption/discontinuation and >= 11-month follow-up who had not restarted treatment maintained the response. Conclusion: Although TKIs are used for long-term CML treatment, physicians sometimes recommend interruptions/discontinuations. In this study, interruptions/discontinuations were mainly caused by side effects or intolerance, rather than TFR attempts. |
| |
Language
|
|
|
|
English
| |
Source (journal)
|
|
|
|
Acta haematologica. - Basel
| |
Publication
|
|
|
|
Basel
:
2019
| |
ISSN
|
|
|
|
0001-5792
| |
DOI
|
|
|
|
10.1159/000499329
| |
Volume/pages
|
|
|
|
142
:4
(2019)
, p. 197-207
| |
ISI
|
|
|
|
000495677400003
| |
Pubmed ID
|
|
|
|
31163431
| |
Full text (Publisher's DOI)
|
|
|
|
| |
Full text (publisher's version - intranet only)
|
|
|
|
| |
|